Thanks to your support, our world-leading research is taking us closer to a world free from MS. And this year, we've seen further progress in MS research – from new laboratory discoveries to long-awaited clinical trial results.

In September, over 9500 MS researchers gathered to share insights on the latest MS research. Caitlin Astbury, our senior research communications manager, shares her highlights from the conference.

We caught up with our Legacies Lead Sarah to find out about her recent visit to the MS Society Tissue Bank.

We met some of the brilliant women from the BartsMS research group at Queen Mary University London. Dr Sharmilee Gnanapavan is a neurologist who specialises in finding new ways of identifying MS progression.

We take a look behind the headlines to see what an mRNA treatment could mean for people living with MS. 

It takes a long time and lots of hard work to develop a new MS treatment. In 2019, ocrelizumab (brand name Ocrevus) became the first drug to be available for people with primary progressive MS on the NHS.

To help people at every stage of MS, we need to stop MS from progressing. Researchers are looking at three ways to do this. And we’ve now reached the point where there are clinical trials in progress for all three.

Recent media reports suggest testosterone plays a role in protecting men against MS. We look behind the headlines to see what the study actually showed.

We spoke to Professors Anna Williams and Charles ffrench-Constant to find about the potential to reverse myelin damage in MS.